What's in Glenmark Specialty S.A.'s pipeline?

Glenmark Specialty S.A. has 9 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Glenmark Specialty S.A.'s portfolio?

Top competitors by shared drug class: ALK-Abelló A/S, Association Asthma, Bulgaria, AstraZeneca, Bausch & Lomb Incorporated, Beijing Tongren Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/glenmark-specialty-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Glenmark Specialty S.A. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glenmark Specialty S.A. pipeline: 0 marketed, 0 filed, 7 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
GMM-2 NS	GMM-2 NS	phase 3
GOM-NS	GOM-NS	phase 3
GSP 301 Placebo NS pH 7.0	GSP 301 Placebo NS pH 7.0	phase 3
GSP 301 NS	GSP 301 NS	phase 3
GSP 301 Placebo NS pH 3.7	GSP 301 Placebo NS pH 3.7	phase 3
Mometasone furoate NS	Mometasone furoate NS	phase 3	Intranasal corticosteroid	Glucocorticoid receptor	Immunology / Allergy / Rhinology
Olopatadine HCl NS	Olopatadine HCl NS	phase 3	H1-receptor antagonist / mast cell stabilizer	H1 receptor	Allergy / Immunology

Therapeutic area mix

Allergy / Immunology · 1
Immunology / Allergy / Rhinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ALK-Abelló A/S · 1 shared drug class
Association Asthma, Bulgaria · 1 shared drug class
AstraZeneca · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Beijing Tongren Hospital · 1 shared drug class
Children's Hospital of Philadelphia · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Glenmark Specialty S.A.:

Cite this brief

Drug Landscape (2026). Glenmark Specialty S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/glenmark-specialty-s-a. Accessed 2026-06-10.